Globus Medical, Inc. (GMED)
NYSE$71.04
Market Cap
$11.36B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
605 of 924
Rank in Industry
75 of 118
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GMED Insider Trading Activity
GMED Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $35,527,949 | 17 | 100 |
Related Transactions
| Norwalk Leslie V | director | 0 | $0 | 2 | $620,574 | $-620,574 |
| Huller Kelly | SVP, GC, Corporate Secretary | 0 | $0 | 3 | $1.19M | $-1.19M |
| Pfeil Keith W | COO, CFO | 0 | $0 | 1 | $1.25M | $-1.25M |
| RHOADS ANN D | director | 0 | $0 | 2 | $1.65M | $-1.65M |
| Lemaitre Dan | director | 0 | $0 | 3 | $5.31M | $-5.31M |
| Davidar David D | director | 0 | $0 | 5 | $10.21M | $-10.21M |
| Scavilla Daniel T | President, CEO | 0 | $0 | 2 | $15.85M | $-15.85M |
About Globus Medical, Inc.
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and …
Insider Activity of Globus Medical, Inc.
Over the last 12 months, insiders at Globus Medical, Inc. have bought $0 and sold $35.53M worth of Globus Medical, Inc. stock.
On average, over the past 5 years, insiders at Globus Medical, Inc. have bought $99,824 and sold $24.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 615 shares for transaction amount of $33,136 was made by Douglas Robert Andrew (director) on 2020‑08‑24.
List of Insider Buy and Sell Transactions, Globus Medical, Inc.
| 2025-02-28 | Sale | RHOADS ANN D | director | 7,500 0.0046% | $78.68 | $590,100 | -5.52% | |
| 2025-01-10 | Sale | Pfeil Keith W | COO, CFO | 14,167 0.0105% | $88.29 | $1.25M | -2.83% | |
| 2024-12-02 | Sale | Huller Kelly | SVP, GC, Corporate Secretary | 2,500 0.0019% | $87.00 | $217,502 | -0.51% | |
| 2024-11-22 | Sale | Davidar David D | director | 13,512 0.01% | $85.00 | $1.15M | -0.95% | |
| 2024-11-22 | Sale | Lemaitre Dan | director | 1,097 0.0008% | $85.02 | $93,263 | -0.95% | |
| 2024-11-21 | Sale | Davidar David D | director | 26,488 0.0195% | $85.00 | $2.25M | -1.15% | |
| 2024-11-21 | Sale | Scavilla Daniel T | President, CEO | 130,000 0.0957% | $85.00 | $11.05M | -1.15% | |
| 2024-11-21 | Sale | Lemaitre Dan | director | 13,278 0.0098% | $85.00 | $1.13M | -1.15% | |
| 2024-11-06 | Sale | Scavilla Daniel T | President, CEO | 60,000 0.0431% | $80.02 | $4.8M | +0.91% | |
| 2024-11-06 | Sale | Huller Kelly | SVP, GC, Corporate Secretary | 5,000 0.0036% | $81.01 | $405,050 | +0.91% | |
| 2024-10-16 | Sale | Davidar David D | director | 50,000 0.0393% | $75.04 | $3.75M | +10.76% | |
| 2024-10-16 | Sale | Huller Kelly | SVP, GC, Corporate Secretary | 7,500 0.0059% | $75.02 | $562,649 | +10.76% | |
| 2024-09-13 | Sale | Davidar David D | director | 25,000 0.0187% | $70.46 | $1.76M | +17.68% | |
| 2024-09-13 | Sale | RHOADS ANN D | director | 15,000 0.0112% | $70.36 | $1.06M | +17.68% | |
| 2024-07-11 | Sale | Norwalk Leslie V | director | 1,000 0.0008% | $70.00 | $70,000 | +6.11% | |
| 2024-05-10 | Sale | Lemaitre Dan | director | 63,300 0.0468% | $64.61 | $4.09M | +12.53% | |
| 2024-05-08 | Sale | Davidar David D | director | 20,000 0.0156% | $65.00 | $1.3M | +17.86% | |
| 2024-03-15 | Sale | Norwalk Leslie V | director | 10,590 0.0079% | $51.99 | $550,574 | +38.56% | |
| 2024-03-01 | Sale | Huller Kelly | SVP, GC, Corporate Secretary | 7,500 0.0055% | $54.10 | $405,730 | +29.73% | |
| 2023-05-15 | Sale | Lemaitre Dan | director | 43,450 0.0436% | $56.98 | $2.48M | -6.08% |
Total: 134
*Gray background shows transactions not older than one year
Insider Historical Profitability
25.46%
| Douglas Robert Andrew | director | 2005 0.0013% | $142,435.20 | 3 | 0 | +25.46% |
GMED Institutional Investors: Active Positions
| Increased Positions | 274 | +57.2% | 15M | +13.4% |
| Decreased Positions | 201 | -41.96% | 13M | -12.21% |
| New Positions | 106 | New | 7M | New |
| Sold Out Positions | 43 | Sold Out | 2M | Sold Out |
| Total Postitions | 552 | +15.24% | 110M | +1.19% |
GMED Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $872,583.00 | 9.45% | 10.86M | +240,218 | +2.26% | 2024-12-31 |
| Blackrock, Inc. | $854,351.00 | 9.25% | 10.64M | +363,165 | +3.54% | 2024-12-31 |
| Janus Henderson Group Plc | $531,302.00 | 5.75% | 6.61M | -382,855 | -5.47% | 2024-12-31 |
| State Street Corp | $288,708.00 | 3.13% | 3.59M | +23,743 | +0.67% | 2024-12-31 |
| Jpmorgan Chase & Co | $225,244.00 | 2.44% | 2.8M | +199,556 | +7.66% | 2024-12-31 |
| Burgundy Asset Management Ltd. | $210,286.00 | 2.28% | 2.62M | +43,330 | +1.68% | 2024-12-31 |
| Citadel Advisors Llc | $206,556.00 | 2.24% | 2.57M | +985,036 | +62.08% | 2024-12-31 |
| Wellington Management Group Llp | $200,527.00 | 2.17% | 2.5M | -81,891 | -3.18% | 2024-12-31 |
| Sculptor Capital Lp | $166,892.00 | 1.81% | 2.08M | -132,900 | -6.01% | 2024-12-31 |
| Geode Capital Management, Llc | $152,384.00 | 1.65% | 1.9M | +12,151 | +0.65% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.